Quick Answer
CASI Pharmaceuticals, Inc. reported Diluted EPS of $2.56 per share (loss) for fiscal year 2024.
CASI Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$2.56 | -26.7% |
| 2023 | -$2.02 | +32.9% |
| 2022 | -$3.01 | -11.9% |
| 2021 | -$2.69 | +38.4% |
| 2020 | -$4.37 | — |
- CASI Pharmaceuticals, Inc. showed a decrease of -26.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2024 period, CASI Pharmaceuticals, Inc.’s diluted eps has grown by 41.4% (from $4.37 per share (loss) to $2.56 per share (loss)).
- The most recent figure is from CASI Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 20-F), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: